May 20, 2022
Shardul Amarchand Mangaldas & Co. advised Dr. Agarwal’s Health Care Limited in the Series D Investment by TPG and Temasek in the company. Existing investor, ADV Partners, exited the company as part of this transaction. The deal was valued at INR 1050 Crores approximately and is India’s largest private-equity transaction in single specialty healthcare and the largest-ever fundraise in the Indian eye care space. The date of closing was 05 May 2022.
The transaction team was led by Amit Khansaheb, Partner; Promode Murugavelu, Partner; Karthika Menon, Principal Associate; Kayal Manivannan, Associate; Sai Dharshini, Associate and Swetha Sethuraman, Associate. Dorothy Thomas, Partner; Raghavi Raj, Associate and Niranjana Pandian, Associate also assisted on the transaction. The competition law team was led by Aparna Mehra, Partner; Rahul Rajiv Shukla, Senior Associate; Karan Arora, Associate and Nimish Malpani, Associate. The securities law team was led by Manjari Tyagi, Partner; Deepika Goyal, Senior Associate and Tanish Prabhakar, Associate.
Veritas Legal advised TPG on Indian legal aspects, J. Sagar Associates advised Temasek on Indian legal aspects and Cyril Amarchand Mangaldas advised ADV on Indian legal aspects.
The Bar Council of India does not permit solicitation of work and advertising by legal practitioners and advocates. By accessing the Shardul Amarchand Mangaldas & Co. website (our website), the user acknowledges that: